US › Healthcare

Assertio Therapeutics Inc (ASRT)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$23.500.00%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$9.9M
Revenue YoY
-62.5%
Net profit
$-18.9M
Profit YoY
-39.3%
EPS
$-2.93
EPS estimate
$-1.91
Net margin
-189.8%

EPS came in at -2.93 against a street estimate of -1.91 — a miss of 53.4%.

Key statistics

Market cap
$151.9M
Forward P/E
56.5
P/B
2.01
Book value
$11.73
EPS (TTM)
$-5.55
52-week high
$28.55
52-week low
$8.72
50-day MA
$21.99
200-day MA
$14.90
Beta
0.53

Analyst view

Analysts rate Assertio Therapeutics Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $24.43.

Shareholding

Insiders
1.97%
Institutions
29.29%

Largest institutional holders

FundStake
Nantahala Capital Management, LLC10.71%
Vanguard Group Inc4.60%
Vanguard Capital Management, LLC4.16%
Opaleye Management Inc4.11%
Renaissance Technologies Corp3.54%
Edgewood Management LLC1.66%
BlackRock Inc1.39%
Jane Street Group LLC1.23%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Assertio Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.